Crystalline FGFR4 inhibitor compound and uses thereof

US11498916B2 · kind B2 · utility

Assignee

• Eisai R&D Management Co., Ltd. · JP

Inventors

• George A. Moniz · Cambridge, US
• Kristen Sanders · Gilmanton, US
• Arani Chanda · Malden, US
• Kenshi Yoshida · Tsukuba, JP
• Ming-Hong Hao · Chesterfield, US
• Dominic Reynolds · Stoneham, US
• Sudeep Prajapati · Somerville, US
• Anand Selvaraj · Boston, US
• Takashi Satoh · Andover, US
• John Wang · Andover, US

Key dates

• Filing date: Dec 20, 2019
• Grant date: Nov 15, 2022
• Expiry date: Dec 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/48
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.